[go: up one dir, main page]

MX2014010005A - Dispersiones en aceite autoconservadas que comprenden acido borico. - Google Patents

Dispersiones en aceite autoconservadas que comprenden acido borico.

Info

Publication number
MX2014010005A
MX2014010005A MX2014010005A MX2014010005A MX2014010005A MX 2014010005 A MX2014010005 A MX 2014010005A MX 2014010005 A MX2014010005 A MX 2014010005A MX 2014010005 A MX2014010005 A MX 2014010005A MX 2014010005 A MX2014010005 A MX 2014010005A
Authority
MX
Mexico
Prior art keywords
self
oil dispersion
boric
preserved
oil dispersions
Prior art date
Application number
MX2014010005A
Other languages
English (en)
Inventor
Jean-Sébastien Garrigue
Fréderic Lallemand
Betty Philips
Original Assignee
Santen Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Sas filed Critical Santen Sas
Publication of MX2014010005A publication Critical patent/MX2014010005A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere a una dispersión en aceite autoconservada. En particular, la presente invención se refiere a una dispersión en aceite autoconservada que incluye una fase oleosa dispersa, una fase acuosa y por lo menos un surfactante, en donde dicha dispersión en aceite contiene ácido bórico en una cantidad que varía de 0.005% a 0.075% en peso del peso total de la dispersión en aceite, dicha cantidad de ácido bórico es una cantidad efectiva como conservante, de tal forma que la dispersión en aceite tiene una actividad conservante.
MX2014010005A 2012-02-23 2013-02-22 Dispersiones en aceite autoconservadas que comprenden acido borico. MX2014010005A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602369P 2012-02-23 2012-02-23
EP12156652.5A EP2630952A1 (en) 2012-02-23 2012-02-23 Self-preserved oil dispersions comprising boric acid
PCT/EP2013/053556 WO2013124415A1 (en) 2012-02-23 2013-02-22 Self-preserved oil dispersions comprising boric

Publications (1)

Publication Number Publication Date
MX2014010005A true MX2014010005A (es) 2015-03-09

Family

ID=45656502

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010005A MX2014010005A (es) 2012-02-23 2013-02-22 Dispersiones en aceite autoconservadas que comprenden acido borico.

Country Status (19)

Country Link
US (1) US9682147B2 (es)
EP (2) EP2630952A1 (es)
JP (2) JP6231499B2 (es)
KR (1) KR20140124405A (es)
CN (1) CN104220048A (es)
AU (1) AU2013224043B2 (es)
CA (1) CA2862932A1 (es)
EA (1) EA201400869A1 (es)
GE (1) GEP20186824B (es)
HK (2) HK1203153A1 (es)
IN (1) IN2014DN06853A (es)
MX (1) MX2014010005A (es)
MY (1) MY169504A (es)
NZ (1) NZ627861A (es)
PH (1) PH12014501906A1 (es)
SG (1) SG11201405098PA (es)
TW (1) TWI564032B (es)
UA (1) UA112669C2 (es)
WO (1) WO2013124415A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2630952A1 (en) * 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
AU2016222902A1 (en) * 2015-02-24 2017-08-31 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
CN108367026A (zh) * 2015-06-18 2018-08-03 常规制药股份公司 抗微生物配制品
US10004683B2 (en) 2015-06-18 2018-06-26 Common Pharma, Inc. Antimicrobial formulations
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017019905A1 (en) * 2015-07-28 2017-02-02 Otonomy, Inc. Treatment using truncated trk b and trk c antagonists
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
PL3231417T3 (pl) * 2016-04-15 2019-05-31 Dr Gerhard Mann Chem Pharm Fabrik Gmbh Odporna na składowanie kompozycja oftalmiczna
US9821510B2 (en) * 2016-04-18 2017-11-21 Xerox Corporation Using depth in three-dimensional object printing to form colors that change with viewing and illumination angles
BE1024559B1 (nl) * 2017-02-21 2018-04-05 Purna Pharmaceuticals Nv Werkwijze voor het maken van een verstuifbare emulsie omvattende een corticosteroïde, een aminoglycoside en een zuur
CN107019669B (zh) * 2017-04-13 2020-01-21 山东天音生物科技有限公司 一种玉米黄质纳米混悬剂及其制备方法
WO2018212846A1 (en) 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use
AU2018367122A1 (en) * 2017-11-14 2020-06-04 Profem Gmbh Emulsions for the topical treatment of dermal infections and mucosal infections
CN112272558A (zh) 2018-04-24 2021-01-26 阿勒根公司 盐酸毛果芸香碱用于治疗眼部病症的用途
MY198184A (en) * 2018-09-21 2023-08-09 Petroliam Nasional Berhad Ionic liquids formulation as an environmentally friendly oil dispersant
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
WO2020210722A1 (en) * 2019-04-11 2020-10-15 R.P. Scherer Technologies, Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
US20230049050A1 (en) * 2019-12-18 2023-02-16 National Research Council Of Canada Emulsions of bioactive lipophilic compounds including oils
WO2021191652A1 (en) * 2020-03-21 2021-09-30 Jafari Javid Mihan Composition and methods for prevention and treatment of vascular disorders
GR1010012B (el) * 2020-05-12 2021-05-27 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον κυκλοσπορινη
TWI819317B (zh) * 2021-06-07 2023-10-21 溫士頓醫藥股份有限公司 含前列腺素衍生物的眼用奈米乳劑組合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW274516B (es) 1993-11-12 1996-04-21 Ciba Geigy Ag
JP4215277B2 (ja) * 1996-08-09 2009-01-28 アルコン ラボラトリーズ，インコーポレイテッド シクロデキストリンを含有する薬学的組成物用防腐剤系
JP4221073B2 (ja) * 1997-02-28 2009-02-12 千寿製薬株式会社 乳剤用保存剤および乳剤
US6379688B2 (en) * 1997-02-28 2002-04-30 Senju Pharmaceutical Co., Ltd. Preservative for emulsion and emulsion containing same
US6166012A (en) 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
US6528070B1 (en) * 2000-09-15 2003-03-04 Stepan Company Emulsion comprising a ternary surfactant blend of cationic, anionic, and bridging surfactants, oil and water, and methods of preparing same
CA2467559A1 (en) * 2001-11-19 2003-05-30 Control Delivery Systems, Inc. Topical delivery of codrugs
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US20060233739A1 (en) * 2003-11-24 2006-10-19 Thornfeldt Carl R Treatment of mucocutaneous disorders through reversing chronic imflammation and barrier disruption
US20060141059A1 (en) 2004-12-27 2006-06-29 Alcon, Inc. Self-preserved ophthalmic pharmaceutical compositions containing tobramycin
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
WO2008036855A2 (en) 2006-09-21 2008-03-27 Alcon Research, Ltd. Self-preserved aqueous pharmaceutical compositions
JP5394927B2 (ja) 2006-09-28 2014-01-22 アルコン リサーチ， リミテッド 自己保存性水性医薬品組成物
SG185273A1 (en) * 2007-10-16 2012-11-29 Sun Pharma Advanced Res Co Ltd Ophthalmic composition comprising a prostaglandin
US8669241B2 (en) 2008-12-02 2014-03-11 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
TWI478730B (zh) * 2009-12-03 2015-04-01 Alcon Res Ltd 眼科乳劑
JP6093701B2 (ja) * 2011-07-08 2017-03-08 ロート製薬株式会社 眼科用水性組成物
EP2630952A1 (en) * 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid

Also Published As

Publication number Publication date
TWI564032B (zh) 2017-01-01
MY169504A (en) 2019-04-15
CN104220048A (zh) 2014-12-17
UA112669C2 (uk) 2016-10-10
GEP20186824B (en) 2018-02-26
US9682147B2 (en) 2017-06-20
PH12014501906A1 (en) 2014-11-24
US20150025020A1 (en) 2015-01-22
EA201400869A1 (ru) 2014-12-30
TW201347786A (zh) 2013-12-01
CA2862932A1 (en) 2013-08-29
JP2018039828A (ja) 2018-03-15
IN2014DN06853A (es) 2015-05-22
WO2013124415A1 (en) 2013-08-29
AU2013224043A1 (en) 2014-08-21
NZ627861A (en) 2016-02-26
KR20140124405A (ko) 2014-10-24
SG11201405098PA (en) 2014-09-26
JP6231499B2 (ja) 2017-11-15
EP2630952A1 (en) 2013-08-28
JP2015509494A (ja) 2015-03-30
AU2013224043B2 (en) 2017-07-27
EP2816998A1 (en) 2014-12-31
HK1203154A1 (en) 2015-10-23
HK1203153A1 (en) 2015-10-23

Similar Documents

Publication Publication Date Title
MX2014010005A (es) Dispersiones en aceite autoconservadas que comprenden acido borico.
WO2013177062A3 (en) Methods for improving safety of blood-brain barrier transport
MX362655B (es) Composiciones cosmeticas.
IN2014MN02042A (es)
PH12015500900B1 (en) A stabilized pemetrexed formulation
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
HK1208375A1 (en) Improved complexes and compositions containing curcumin
WO2013188366A3 (en) Nanosystems for formulation of effective minimum risk biocides
MX2019002609A (es) Estabilizacion quimica de sal sodica de yodosulfuron-metilo mediante hidroxiestearatos.
MX2013010812A (es) Formulacion farmaceutica que comprende inositol.
NZ718927A (en) Pesticide emulsion concentrates containing natural or petroleum derived oils and methods of use
NZ706983A (en) Treating soluble coffee
FR2969652B1 (fr) Utilisation de dispersions de particules de fer comme additif de carburant
WO2012146887A9 (en) Formulation component
PH12015501013A1 (en) Bar soap composition and method of manufacture
IN2015DN03337A (es)
MX354514B (es) Extracto de cafe que contiene acido protocatecuico y su uso en agroquimica contra patogenos de plantas.
GB201209838D0 (en) Piston device
MY171477A (en) Stable emulsions of polyisobutene and their use
MX2016003501A (es) Concentrado liquido para la proteccion de composiciones que van a aplicarse topicamente, contra ataque microbiano.
WO2014184660A3 (en) Emulsion stabilization
WO2013037752A3 (en) Foaming oil composition
Bannai et al. Maximal m-distance sets containing the representation of the Johnson graph J (n, m)
NZ745636A (en) Topical parasiticidal formulation
MX2012002356A (es) Métodos termoquímicos para obtener dispersiones líquidas a base de agua, de insecticidas piretroides.